December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

21.21 -0.81 (-3.68%)
Streaming Delayed Price Updated: 9:54 AM EDT, Sep 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
36 37 Next >
News headline image
Sarepta Stock Slumps After FDA Opens Probe Into Patient Death, Analyst Sounds Alarm ↗
H.C. Wainwright reiterated a ‘Sell’ rating on Sarepta on Wednesday with a $10 price target. The firm views the FDA as a potential headwind for Sarepta now. 
Via Stocktwits
Topics Artificial Intelligence Death
News headline image
This Sarepta Therapeutics Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday ↗
 
Via Benzinga
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
Via ACCESS Newswire
News headline image
Assessing Sarepta Therapeutics: Insights From 38 Financial Analysts ↗
 
Via Benzinga
News headline image
BFA Law Notifies Sarepta Therapeutics, Inc. (SRPT) Investors that the Company is being Investigated for Securities Fraud - Contact the Firm if You Lost Money
Via ACCESS Newswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
Via ACCESS Newswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
From Pomerantz LLP
Via GlobeNewswire
News headline image
SRPT FRAUD NOTIFICATION: Did Sarepta Therapeutics, Inc. Commit Securities Fraud? Investors are Urged to Contact BFA Law
Via ACCESS Newswire
News headline image
SRPT REVIEW: Sarepta Therapeutics, Inc. is Being Investigated for Securities Fraud After Elevidys Death - Investors Are Urged to Contact BFA Law
Via ACCESS Newswire
News headline image
Analyst Downgrades Sarepta As Elevidys Safety Clouds Future Demand ↗
Sarepta shares face pressure after a second Elevidys-linked death and analyst downgrade over safety concerns and lowered revenue prospects. 
Via Benzinga
News headline image
This Sarepta Therapeutics Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Friday ↗
 
Via Benzinga
News headline image
The FDA Shake-Up Continues, And Could Impact Genetic Medicines ↗
Nicole Verdun and Rachael Anatol were placed on administration leave without explanation. 
Via Investor's Business Daily
Topics Government
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
Via ACCESS Newswire
News headline image
2 Growth Stocks with All-Star Potential and 1 to Ignore
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s... 
Via StockStory
Topics Artificial Intelligence
News headline image
SRPT INQUIRY NOTICE: Lose Money on Sarepta Therapeutics, Inc.? Contact BFA Law About its Securities Fraud Investigation
Via ACCESS Newswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
From Pomerantz LLP
Via GlobeNewswire
News headline image
Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences
After a second patient passed away, Sarepta Therapeutics crashed. Solid Biosciences rose over 10% in response. Wall Street sees big upside in both names. 
Via MarketBeat
Topics Earnings
News headline image
SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors With Significant Losses to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud
News headline image
SRPT Investigation Reminder: Kessler Topaz Meltzer &amp; Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors With Significant Losses to Contact the Firm
Via TheNewswire.com
Topics Fraud
News headline image
SRPT BREAKING NEWS: Sarepta Therapeutics, Inc. is being Investigated for Securities Fraud after Second Elevidys Death; Investors with Losses are Notified to Contact BFA Law
From Bleichmar Fonti & Auld LLP
Via Business Wire
News headline image
US Stock Futures Tumble After Trump Threatens 'Real End' To Iran's Nuclear Problem: '...Avoid Getting Whipsawed By Noise,' Says Expert ↗
U.S. stock futures were trading lower on Tuesday following Monday's advanced. Futures of major benchmark indices were lower in premarket. 
Via Benzinga
Topics Government
News headline image
Market Monitor News June 17 (ROKU, Advanced Micro Devices UP - Sarepta Therapeutics DOWN) ↗
Markets rebound on hopes of Iran de-escalation; oil drops, Roku surges on Amazon deal, Fed decision looms. 
Via Chartmill
Topics Economy
News headline image
Dow Surges Over 300 Points As Iran Signals De-Escalation: Investor Sentiment Improves, Fear Index Remains In 'Greed' Zone ↗
 
Via Benzinga
Topics Stocks
News headline image
1 Oversold Stock Primed to Rebound and 2 to Steer Clear Of
The past year hasn't been kind to the stocks featured in this article. Each has tumbled to their lowest points in 12 months, leaving investors to decide whether they're witnessing fire sales or falling... 
Via StockStory
News headline image
SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors With Significant Losses to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud
News headline image
SRPT Investigation Reminder: Kessler Topaz Meltzer &amp; Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors With Significant Losses to Contact the Firm
Via TheNewswire.com
Topics Fraud
News headline image
Monday's session: top gainers and losers ↗
Curious to know what's happening on the US markets one hour before the close of the markets on Monday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
News headline image
S&P 500 Surges 1%; New York Manufacturing Activity Tumbles In June ↗
 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
What the Options Market Tells Us About Sarepta Therapeutics ↗
 
Via Benzinga
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
36 37 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.